More Videos
SPECIAL REPORT
MOST SHARED
- Wednesday's Economic News Crunch Could Tilt Markets
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Obama Reiterates Commitment to Boost US-India Ties
- NBA D-League On The Rise
- The Social Media Gaming Threat
- Australia Wheat Exporters Face Challenges: GrainCorp
- Japan Export Rebound Eases Fear of New Recession
- Stifling Anger at Work Can Kill, Survey Finds
- Citi Mortgage Reveals What Treasury Won't
- S&P to Hit 1,200 by Year-End: Chief Investor
- Amended Berkshire Hathaway Filing Indicates No Secret Stock Stakes at End of Q3
- Facebook's Biggest-Ever Holiday Shopping Season
- Facebook's New Dual Class Structure - Slow Steps to an IPO
- 5 Big Bank Stocks Investors Should Consider: Strategists
- Gambling Drunk, Texting to Live And America's On Sale - Your Emails
- Nov. 24: Unusual Volume Leaders
- NBA D-League On The Rise
- Americans Ditch Planes for Trains this Thanksgiving
- AIG Board OKs CEO Pay; Benmosche Agrees to Stay
- Half of Banks' Losses May Still Be Hidden: IMF Head
- Obama Reiterates Commitment to Boost US-India Ties
- FDIC's Bair Cautions on Risks in Bank Break-Up Plan
- Wednesday's Economic News Crunch Could Tilt Markets
- Call Me Crazy: Confessions of a Black Friday Shopper
- Turkey Day 101: How Well Do You Know Your Bird?
- Citi Mortgage Reveals Something the US Treasury Won't
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
Text Size 
 |
In my reporting, I always try to keep it simple. Particularly in the middle of the credit crisis, too much financial jargon goes over the heads of most people. The same can be said for biopharma coverage. The challenge for reporters is to make the stuff comprehensible for readers, viewers and listeners. But I think it's also incumbent on corporate communications folks to try to communicate in plain English.
So, this morning, partners Roche and Genentech[DNA
Loading...
()
] issued separate press releases on positive test results on their drug Rituxan for a form of leukemia. DNA also shares Rituxan with Biogen Idec[BIIB
Loading...
()
]. Genentech's release reads like this: "Rituxan in combination with fludarabine and cyclophosphamide chemotherapy met its primary endpoint of improving progression-free survival, as assessed by investigators, in patients with previously treated CD-20-positive chronic lymphocytic leukemia compared to chemotherapy alone." Come again?
Fortunately, someone at Roche found a clearer, more succinct way to put it. "Patients treated with (Rituxan) in combination with current standard chemotherapy were able to significantly extend the amount of time they lived without their disease progressing, compared to patients treated with chemotherapy alone." That's pretty close to how I would've written it for presentation on CNBC.
I suspect that oftentimes the scientists and lawyers have too much of a hand in writing this stuff. Let communications people communicate. There's a way to balance the rigors of the law and medicine without getting so bogged down in arcane language that is only decipherable by experts, doctors and analysts. In the news biz, it's called, "dumbing it down." And I don't mean that in a bad or offensive way. It can actually be helpful.
Clarification: Eli Lilly's[LLY
Loading...
()
] press release yesterday about the ImClone [IMCL
Loading...
()
]deal said, "The transaction is not subject to any financing condition...." I was mistaken to interpret that to mean no financing was needed. LLY is going to finance part of the all-cash deal with debt. In my interview with CEO John Lechleiter on "Squawk Box" Monday he said, "We're very confident in our ability to finance this deal."
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes